Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 7/20 | 0.80 |
| ▸ | TSHR | P16473 | 4/20 | 0.70 |
| ▸ | HTT | P42858 | 4/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | CD74 | P04233 | 5/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20725150 | 0.92 | MIF (0.71) | MIFTSHRHTTSMN1; SMN2LMNA | |
| SCHEMBL20725151 | 0.90 | MIF (0.76) | MIFTSHRHTTSMN1; SMN2LMNA | |
| SCHEMBL2757851 | 0.89 | MIF (1.00) | MIFTSHRHTTSMN1; SMN2LMNA | |
| SCHEMBL14898603 | 0.81 | MIF (0.82) | MIFTSHRHTTSMN1; SMN2LMNA | |
| SCHEMBL10874258 | 0.81 | MIF (1.00) | MIFTSHRHTTSMN1; SMN2LMNA | |
| SCHEMBL18805701 | 0.80 | MIF (0.65) | MIFTSHRHTTSMN1; SMN2LMNA | |
| SCHEMBL29566121 | 0.80 | MIF (0.65) | MIFTSHRHTTSMN1; SMN2LMNA | |
| SCHEMBL20725153 | 0.79 | ALDH1A1 (0.67) | MIFTSHRHTTSMN1; SMN2LMNA | |
| SCHEMBL18805678 | 0.79 | MIF (0.79) | MIFTSHRHTTSMN1; SMN2LMNA | |
| SCHEMBL16296890 | 0.79 | TSHR (0.80) | MIFTSHRHTTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9643922-B2 | MIF modulators | YALE UNIVERSITY (US) | 2017-05-09 | — | — | US | claimed |
| US-20230404980-A1 | METHODS OF TREATING SPONDYLOARTHRITIS OR SYMPTOMS THEREOF | UNIVERSITY HEALTH NETWORK (CA) | 2023-12-21 | — | — | US | disclosed |
| EP-4237002-A1 | METHODS OF TREATING SPONDYLOARTHRITIS OR SYMPTOMS THEREOF | University Health Network (CA) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022087719-A1 | METHODS OF TREATING SPONDYLOARTHRITIS OR SYMPTOMS THEREOF | UNIVERSITY HEALTH NETWORK (CA) | 2022-05-05 | — | — | WO | disclosed |
| US-10202343-B2 | MIF modulators | YALE UNIVERSITY (US) | 2019-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202343-B2 | MIF modulators | MIF, HMGB2, HMGB3 | MIF 1/4885TSHR 2619/4885HTT 3674/4885 |
| US-20230404980-A1 | METHODS OF TREATING SPONDYLOARTHRITIS OR SYMPTOMS THEREOF | MIF, SPAST, MMP12 | MIF 1/4885TSHR 4177/4885HTT 3094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.